Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

• Published in: Frontiers in oncology Vol. 13
• Main Authors: Piringer, Gudrun, Decker, Jörn, Trommet, Vera, Kühr, Thomas, Heibl, Sonja, Dörfler, Konrad, Thaler, Josef
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 05-05-2023
• Subjects: BRAF-V600 mutation; combination targeted therapy; dabrafenib; MSS; Oncology; trametinib
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1166545

Metastatic BRAF
V600E
mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAF
V600E
mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer. Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAF
V600E
mutated, microsatellite-stable colon cancer. This patient achieved a complete response after 1 year of triple therapy. Due to skin toxicity grade 3 and recurrent urinary tract infections due to mucosal toxicity, a therapy de-escalation to dabrafenib and trametinib was performed, and the double therapy was administered for further 41 months with ongoing complete response. For 1 year, the patient was off therapy and is still in complete remission.